Jefferies Group LLC reaffirmed a "hold" rating and issued a $68.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, July 14th. Ptc Inc now has $6.40 billion valuation. The last stock price is up -22.84% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same period. About shares traded. Greenbrier Companies Inc (NYSE:GBX) has risen 66.79% since September 12, 2016 and is uptrending. It has outperformed by 40.53% the S&P500. Moreover, Emerald Advisers Inc Pa has 1.01% invested in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, July 27th. Capital Research Global Investors now owns 5,183,330 shares of the biopharmaceutical company's stock valued at $321,937,000 after buying an additional 71,811 shares during the last quarter.
The company is now down since yesterday's close of 50. It has underperformed by 23.19% the S&P500.
Investors sentiment decreased to 1.07 in Q4 2016. The biopharmaceutical company reported ($1.64) EPS for the quarter, missing the consensus estimate of ($1.53) by $0.11. Sold All: 17 Reduced: 56 Increased: 54 New Position: 24.
Ironbridge Capital Mgmt Ltd Partnership reported 30,820 shares or 0.1% of all its holdings. Rhenman & Partners Asset Management Ab owns 35,573 shares worth $2,209,000. Blackrock Institutional Na has invested 0.01% in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). "(NASDAQ:RARE) Stock Rating Reaffirmed by Stifel Nicolaus" was originally posted by Week Herald and is the sole property of of Week Herald. Bnp Paribas Arbitrage invested in 9,180 shares. Tower Cap Limited Liability Co (Trc) holds 0% of its portfolio in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) for 465 shares. Advisory holds 4.55% or 8.54M shares. Putnam Invs Ltd Co holds 85,583 shares.
Ultragenyx Pharmaceutical Inc., launched on June 13, 2011, is a clinical-stage biopharmaceutical company. Sunbelt Incorporated holds 86 shares. Alphabet Inc Cl C was reduced too. Also, the number of funds holding Ultragenyx Pharmaceutical Inc in their top 10 equity positions was flat from 1 to 1 for the same number.
Ratings analysis reveals 55% of Ultragenyx Pharmaceutical Inc's analysts are positive. HC Wainwright reissued a "neutral" rating and issued a $75.00 target price (up from $72.00) on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 8th. The firm has "Neutral" rating by Bank of America given on Thursday, February 25. As per Friday, October 7, the company rating was initiated by Brean Capital.
On August 23 the company was downgraded to "Hold" from "Buy" and a price target of $55.00 was set in a report from SunTrust Robinson Humphrey. BidaskClub upgraded Ultragenyx Pharmaceutical from a "sell" rating to a "hold" rating in a research note on Tuesday, June 20th. Finally, Leerink Swann reiterated an "outperform" rating and issued a $90.00 price objective (down previously from $94.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, November 14th.
Barclays PLC started coverage on shares of Ultragenyx Pharmaceutical Inc. The rating was maintained by Evercore on Wednesday, July 19 with "Buy".
Boston Advisors Llc decreased Comcast Corp New Cl A (NASDAQ:CMCSA) stake by 446,697 shares to 368,515 valued at $25.45M in 2016Q4. It also upped Sears Hldgs Corp (Put) (NASDAQ:SHLD) stake by 89,700 shares and now owns 138,500 shares.
Investors sentiment increased to 1.84 in 2016 Q4. Its down 1.95, from 1.95 in 2016Q3.
Several institutional investors and hedge funds have recently bought and sold shares of RARE.
These funds have shifted positions in (RARE). Morgan Stanley has 136,060 shares for 0% of their portfolio. Ameriprise Financial has 492,540 shares. Jupiter Asset Management Limited invested in 219,248 shares. Hsbc Holdings Public Limited Co owns 9,634 shares. (NYSE:T). Cap Guardian stated it has 0.03% of its portfolio in AT&T Inc. State Board Of Administration Of Florida Retirement System reported 18,573 shares. Wellington Mngmt Group Inc Llp owns 5.26M shares. Us Bancshares De has 141,599 shares for 0.02% of their portfolio. 143,731 were reported by Tiaa Cref Invest Mngmt Lc. It is 0.00% or $0 reaching $12.99 per share. Bragg Fin Advsr holds 0.55% of its portfolio in Greenbrier Companies Inc (NYSE:GBX) for 79,693 shares.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.